Identification of drug repurposing candidates based on a miRNA-mediated drug and pathway network for cardiac hypertrophy and acute myocardial infarction

Sun, Jiantao; Yang, Jiemei; Chi, Jing; Ding, Xue; Lv, Nan

doi:10.1186/s40246-018-0184-0

Cited by 6 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The FoxO signaling pathway is involved in cell proliferation [46], and Wnt pathways are involved in the control of gene expression, cell behavior, cell adhesion, and cell polarity [47]. Taken together, these results and previous reports [48] have suggested that MAPK, FoxO, and Wnt signaling pathways are of great significance for normal physiological functioning of cardiomyocytes.…”

Section: The Mirna Characteristics Of Isoprenaline-induced Cardiac Hypertrophysupporting

confidence: 68%

The Expression of microRNA in Adult Rat Heart with Isoproterenol-Induced Cardiac Hypertrophy

Gan

Zhang

Yuan

et al. 2020

Cells

View full text Add to dashboard Cite

Cardiac hypertrophy is a common pathological condition and an independent risk factor that triggers cardiovascular morbidity. As an important epigenetic regulator, miRNA is widely involved in many biological processes. In this study, miRNAs expressed in rat hearts that underwent isoprenaline-induced cardiac hypertrophy were identified using high-throughput sequencing, and functional verification of typical miRNAs was performed using rat primary cardiomyocytes. A total of 623 miRNAs were identified, of which 33 were specifically expressed in cardiac hypertrophy rats. The enriched pathways of target genes of differentially expressed miRNAs included the FoxO signaling pathway, dopaminergic synapse, Wnt signaling pathway, MAPK (mitogen-activated protein kinase) signaling pathway, and Hippo signaling pathway. Subsequently, miR-144 was the most differentially expressed miRNA and was subsequently selected for in vitro validation. Inhibition of miR-144 expression in primary myocardial cells caused up-regulation of cardiac hypertrophy markers atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). The dual luciferase reporter system showed that ANP may be a target gene of miR-144. Long non-coding RNA myocardial infarction associated transcript (LncMIAT) is closely related to heart disease, and here, we were the first to discover that LncMIAT may act as an miR-144 sponge in isoproterenol-induced cardiac hypertrophy. Taken together, these results enriched the understanding of miRNA in regulating cardiac hypertrophy and provided a reference for preventing and treating cardiac hypertrophy.

show abstract

Section: The Mirna Characteristics Of Isoprenaline-induced Cardiac Hypertrophysupporting

confidence: 68%

The Expression of microRNA in Adult Rat Heart with Isoproterenol-Induced Cardiac Hypertrophy

Gan

Zhang

Yuan

et al. 2020

Cells

View full text Add to dashboard Cite

show abstract

“…In this way, one other promising alternative on which this review focuses is drug repurposing, also called repositioning (Mercorelli et al, 2018). This therapeutic shift is the subject of several studies in different pathologies including cancer (Sleire et al, 2017), heart diseases (Sun et al, 2018), Alzheimer's disease (Kim, 2015) or depression (Ebada, 2017).…”

Section: Introductionmentioning

confidence: 99%

Drug Repurposing to Fight Colistin and Carbapenem-Resistant Bacteria

Peyclit

Baron

Rolain

2019

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

The emergence of new resistance mechanisms, the failure of classical antibiotics in clinic, the decrease in the development of antibiotics in the industry are all challenges that lead us to consider new strategies for the treatment of infectious diseases. Indeed, in recent years controversy has intensified over strains resistant to carbapenem and/or colistin. Various therapeutic solutions are used to overcome administration of last line antibiotics. In this context, drug repurposing, which consists of using a non-antibiotic compound to treat multi-drug resistant bacteria (MDR), is encouraged. In this review, we first report what may have led to drug repurposing. Main definitions, advantages and drawbacks are summarized. Three major methods are described: phenotypic, computational and serendipity. In a second time we will focus on the current knowledge in drug repurposing for carbapenem and colistin-resistant bacteria with different studies describing repurposed compounds tested on Gram-negative bacteria. Furthermore, we show that drug combination therapies can increase successful by drug repurposing strategy. In conclusion, we discuss the pharmaceutical industries that have little interest in reprofiling drugs due to lack of profits. We also consider what a clinician might think of the indications of these uncommon biologists to treat MDR bacterial infections and avoid therapeutic impasses.

show abstract

“…Another example in a recent study analyzed the topological features of a miRNAgene-drug network and identified miRNA-gene-drug triplets in cardiac hypertrophy and acute myocardial infarction; it later used the miRNA dysregulated pathways to identify novel drug repurposing candidates [49].…”

Section: Cardiovascular Diseasesmentioning

confidence: 99%

Drug Repurposing Using Biological Networks

2021

View full text Add to dashboard Cite

Drug repositioning is a strategy to identify new uses for existing, approved, or research drugs that are outside the scope of its original medical indication. Drug repurposing is based on the fact that one drug can act on multiple targets or that two diseases can have molecular similarities, among others. Currently, thanks to the rapid advancement of high-performance technologies, a massive amount of biological and biomedical data is being generated. This allows the use of computational methods and models based on biological networks to develop new possibilities for drug repurposing. Therefore, here, we provide an in-depth review of the main applications of drug repositioning that have been carried out using biological network models. The goal of this review is to show the usefulness of these computational methods to predict associations and to find candidate drugs for repositioning in new indications of certain diseases.

show abstract

Identification of drug repurposing candidates based on a miRNA-mediated drug and pathway network for cardiac hypertrophy and acute myocardial infarction

Cited by 6 publications

References 36 publications

The Expression of microRNA in Adult Rat Heart with Isoproterenol-Induced Cardiac Hypertrophy

The Expression of microRNA in Adult Rat Heart with Isoproterenol-Induced Cardiac Hypertrophy

Drug Repurposing to Fight Colistin and Carbapenem-Resistant Bacteria

Drug Repurposing Using Biological Networks

Contact Info

Product

Resources

About